Ocaliva, a farsenoid X receptor agonist, won the FDAs accelerated approval for PBC in May 2016
Brazil rejected public reimbursement in 2024, yet private demand persists in major urban centers
Sustainable weight loss, metabolic optimization, and longevity require a comprehensive approach: Choose the right GLP-1 based on individual metabolic needs (semaglutide, tirzepatide, or retatrutide)
they will help in making treatment decisions in diabetes management
This directly addresses the increased appetite and carbohydrate cravings commonly reported during hormonal transitions
HSA and FSA accounts cover PlexusDx medications, offering tax-advantaged savings on top of already-reduced pricing